GB2400565A — Nasal drug delivery device for delivering active material to the turbinate region of the nose
Assigned to Consort Medical Ltd · Expires 2004-10-20 · 22y expired
What this patent protects
A method for delivering an active material <B>37</B> such as a drug aerosol to the turbinate regions <B>4</B>, <B>6, 8</B> of the nose comprises administering to a nostril the active material <B>37</B> in the form of particles havin…
USPTO Abstract
A method for delivering an active material <B>37</B> such as a drug aerosol to the turbinate regions <B>4</B>, <B>6, 8</B> of the nose comprises administering to a nostril the active material <B>37</B> in the form of particles having an aerodynamic diameter below about 12m together with a volume of gas. The volume of gas exceeds the volume of the nasal vestibule <B>2</B> but does not substantially exceed the combined volume of the nasal vestibule <B>2</B> and the turbinate region <B>4, 6, 8.</B> The device substantially prevents further gas flow through the nostril for a predetermined amount of time. The volume of gas may be in the region of 1-30ml and the length of time 0.5 to 30 seconds. Also disclosed is a device for delivering active material <B>37</B> to the nasal turbinate region <B>4, 6, 8</B> comprising a nozzle <B>6</B> forming a gas tight seal with the nostril, a housing <B>1</B>, delivery means and means for indicating when either a predetermined time period has passed or a predetermined volume has passed through the nozzle <B>6.</B>
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.